"Coronavirus: Oxford vaccine triggers immune response"

gracielle

Registered
5 November 2020
Interview...Sarah Gilbert, the scientist who led the Oxford coronavirus vaccine project: "We have to wait for the results of phase 3"
A referent in the area, she spoke with Clarín. She stressed that candidates must show results before being used outside of clinical trials....
 

gracielle

Registered
8 November 2020
Coronavirus: Argentina bought 22 million doses of Oxford vaccine....The first batch would arrive in February.
It was reported by the AstraZeneca laboratory in a statement. The Minister of Health, Ginés González García, reported that the first delivery is expected in early 2021....
....With regard to the AstraZeneca vaccine, the head of the Health portfolio reported that "a first batch would arrive in February, and another in March."...
 

jeff1234

Registered
Sorry if this has already been answered, will there be vaccines available here, other than Sputnik 5? If not where will we likely have to travel to for a Pfizer or AstraZeneca innoculation?
 

gracielle

Registered
Sorry if this has already been answered, will there be vaccines available here, other than Sputnik 5? If not where will we likely have to travel to for a Pfizer or AstraZeneca innoculation?
Also read thread for news/data re: the other vaccines which may become available in ARG....COVID-19 vaccine development pipeline gears up....
You will find the latest update on Page 13.
 

gracielle

Registered
11 November 2020
Hugo Sigman explained how the AstraZeneca vaccine will be distributed in Argentina
Given the uncertainty that still exists as to how the different vaccines will be distributed, Hugo Sigman, shareholder and CEO of the Local Insud group, owner of the mAbxience laboratory that will manufacture the active ingredients for the vaccine Astra Zeneca, explained via Twitter how the manufacturing and distribution process will be done.

....The local firm agreed to manufacture between 150 and 250 million dose. At @mAbxience we will manufacture the active principle, that is, the raw material of the Oxford vaccine. Once completed, the product will be delivered to AstraZeneca, which will send it to Mexico, where the @Liomont laboratory will take care of dividing and packaging it, " said the businessman.

The second step of the process begins in Mexico, "where AstraZeneca will distribute the vaccine equitably in Latin America (with the exception of Brazil, which reached a separate agreement)," explained a partner of Grupo Insud.

However, the businessman clarified that the order will depend on the clinical studies giving positive results and the vaccine being approved by regulatory agencies.

The local laboratory interrupted its usual production to dedicate itself to the production of the vaccine asset. "We are confident that the trials will be successful and we are proud to be part of this project," Sigman concluded.
 

gracielle

Registered
For 45 million local population??
I guess they don't expect it to be very effective.
"The local firm agreed to manufacture between 150 and 250 million dose". Re: that stated amount, it refers to..."AstraZeneca will distribute the vaccine equitably in Latin America (with the exception of Brazil, which reached a separate agreement). For Brazil AstraZeneca is using a laboratory(s) to manufacture the active ingredient in that country for their population.
 

gracielle

Registered
14 November 2020
Coronavirus: Hugo Sigman told when the production of the AstraZeneca vaccine begins in the country
The doctor and CEO of Grupo Insud, Hugo Sigman, in charge of the laboratory that will produce the raw material for the Oxford vaccine, confirmed that production will begin in the country within two weeks.

"We are two weeks away from starting production which begins on November 23", revealed the businessman during the meeting held by the Foundation for Health and Social Security Studies (FESS) in its 9th annual Conference on Social Responsibility in Health and Environment.
"It is a privilege for us to have this opportunity, because the AstraZeneca vaccine is going to be a milestone in the history of world medicine," said Sigman. The doctor also highlighted the "no profit" character that the future vaccine will have, which, as he clarified again, will have an economic value that will range between $3 and $4 dollars....

All these vaccines will be available, if there is no incident, between the end of this year and the beginning of the first quarter of 2021," anticipated the renowned businessman....


Marketing and distribution

A few days after the announcement that the Government bought 22 million doses of the Oxford vaccine, Sigman had already provided this week some details on how it will be commercialized and distributed....The agreed price, he says, is $4, "substantially lower than other companies' vaccines."

Who markets the vaccine

"In other words, AstraZeneca is the one who sells the vaccine. Neither mAbxience nor Liomont can sell the vaccine, neither to governments nor to private parties. AstraZeneca has commissioned us a minimum of 150 million doses and a maximum of 250 million doses," he details Sigman.

According to the businessman, this request depends on the clinical studies giving positive results and the vaccine being approved by the corresponding regulatory agencies, including ANMAT.
 
Last edited:

gracielle

Registered
19 November 2020
....Yesterday, in an interview with A24, the President also predicted that the AstraZeneca-Oxford vaccine will be available from March. "Pfizer had promised to bring the vaccine to around 750 thousand people in the month of December, now that delivery has been delayed a bit," he added. The Government also bet to receive as soon as possible a special batch from a vaccine bank coordinated by the World Health Organization.
 

gracielle

Registered
19 November 2020
The second phase of clinical testing of the vaccine against covid-19 developed by the English University of Oxford shows that it is safe in healthy older people and causes an immune response, reports the medical journal The Lancet on Thursday
....The authors acknowledge that their experiment "has limitations", for example that the oldest people had an average age of 73 or 74 years and were healthy, which does not reflect the situation in nursing homes.
In addition, they add, the majority of volunteers of any age were white and non-smokers, so in the third phase of the clinical trials, the tests will be extended to people of different backgrounds....
 
Top